Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

MiraLAX laxative launched in February helped drive Consumer Health Care third-quarter sales up 5% to $273 mil., Schering-Plough reports during Oct. 22 analyst call. The brand is second in its category in the U.S. with a 7% market share, the firm says. Trailing market leader Metamucil in the laxative/stimulant segment, MiraLAX had dollar sales of $12.1 mil. in food, drug and mass retailers for the 13 weeks ended Sept. 30, according to IRI data. MiraLAX was the first Rx-to-OTC switch in the laxatives category in over 30 years (1"The Tan Sheet" Dec. 11, 2006, p. 7). Also driving growth was Claritin (loratadine) with sales up 9% to $104 mil. OTC sales grew 17% to $162 mil., offset by a 33% decline in sun care sales. Adjusted net revenues increased 12% to $3.5 bil. and profit was $713 mil...

You may also be interested in...

S-P Brings New Laxative Class To OTC Market Under Braintree Licensing Deal

Schering-Plough will position Braintree Laboratories' MiraLAX laxative as an effective treatment for occasional constipation without "harsh" side effects linked to other OTC laxative products

MoCRA Registrants Encouraged By Glimpse Into Cosmetics Direct Portal, But Apprehensions Remain

Jessica O’Connell, partner at Covington & Burling, is getting questions from clients about the electronic system the FDA plans to launch in coming weeks for cosmetics manufacturers to register facilities and list products as required by new cosmetics regulations. It remains to be seen how hard the 29 December 2023 deadline will be for companies to get their information submitted.

Copay Accumulators: Pending CMS Reg May Offer More Clarity After Judge Limits Scope

Programs only allowed for brands with generic competition under court ruling, but related programs such as copay maximizers and so-called ‘alternative funding’ programs are not directly impacted by the decision.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts